Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
CN Stock MarketDetailed Quotes
Dizal Pharmaceutical (688192)
- 67.89
- +2.89+4.45%
Market Closed Jan 16 15:00 CST
31.31BMarket Cap-36.09P/E (TTM)
69.69High65.00Low5.04MlotVolume65.00Open65.00Prev Close343.03MTurnover1.11%Turnover RatioLossP/E (Static)461.19MShares86.1852wk High21.48P/B30.97BFloat Cap40.5152wk Low78.00Limit Up456.25MShs Float86.18Historical High52.00Limit Down7.22%Range %19.02Historical Low--Dividend TTM68.00Avg Price2.03MlotAsk--Div Yield TTM1Lot Size2.48MlotBid
Dizal Pharmaceutical (688192) Income Statement
All
YOY
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 73.23%586.3M | 74.40%355M | 96.32%159.64M | 294.24%359.9M | 743.97%338.45M | 203.55M | 81.32M | 91.29M | 40.1M | 0 |
| Operating revenue | 73.23%586.3M | 74.40%355M | 96.32%159.64M | 294.24%359.9M | 743.97%338.45M | --203.55M | --81.32M | --91.29M | --40.1M | --0 |
| Total operating cost | 19.65%1.23B | 15.68%779.61M | 12.98%382.02M | 8.32%1.36B | 15.09%1.03B | 25.67%673.94M | 34.53%338.13M | 59.55%1.25B | 63.67%896.48M | 44.66%536.26M |
| Operating cost | 229.03%25.33M | 227.59%15.63M | 243.84%7.07M | 189.80%9.32M | 349.71%7.7M | --4.77M | --2.06M | --3.21M | --1.71M | ---- |
| Operating tax surcharges | 42.42%2.2M | 8.63%1.18M | 56.14%379.4K | 141.62%2.04M | 176.77%1.55M | 218.28%1.09M | 44.90%242.98K | 122.48%844.64K | 139.57%559.3K | 92.37%341.77K |
| Operating expense | 31.38%423.74M | 31.98%268.44M | 35.03%123.55M | 112.01%445.33M | 137.54%322.54M | 166.53%203.39M | 155.90%91.5M | 814.19%210.05M | --135.78M | --76.31M |
| Administration expense | -0.09%116.28M | -3.57%69.71M | -8.98%32.5M | -32.55%153.45M | -34.65%116.39M | -38.06%72.29M | -38.31%35.71M | 115.71%227.5M | 129.34%178.09M | 146.95%116.71M |
| Financial expense | 43.09%22.7M | 69.98%16.39M | 112.55%8.18M | 324.08%23.03M | 1,054.70%15.86M | 1,908.51%9.64M | 321.81%3.85M | 165.83%5.43M | 112.72%1.37M | 91.58%-533.1K |
| -Interest expense (Financial expense) | 52.78%23.59M | 81.08%17.15M | 99.94%8.5M | 200.43%22.75M | 243.68%15.44M | 325.76%9.47M | 315.30%4.25M | 74.39%7.57M | 37.99%4.49M | 3.54%2.22M |
| -Interest Income (Financial expense) | -12.58%-1.84M | -35.25%-1.46M | 9.48%-562.29K | 38.42%-2.24M | 43.05%-1.64M | 51.98%-1.08M | 43.36%-621.16K | -44.15%-3.64M | -36.96%-2.87M | -108.90%-2.25M |
| Research and development | 13.48%644.24M | 6.66%408.27M | 2.72%210.33M | -10.17%723.69M | -1.94%567.73M | 11.45%382.77M | 30.75%204.77M | 21.23%805.6M | 20.45%578.96M | 4.20%343.44M |
| Credit Impairment Loss | -268.53%-1.01M | -45.73%-551.95K | -779.37%-211.37K | 129.86%118.26K | ---273.02K | ---378.74K | --31.11K | -2,192.61%-395.99K | ---- | ---- |
| Other net revenue | ||||||||||
| Fair value change income | 69.77%18.55M | 52.22%11.22M | -5.89%3.61M | -35.83%14.45M | -40.31%10.93M | -43.55%7.37M | -46.81%3.83M | -46.59%22.52M | -44.82%18.31M | -43.87%13.06M |
| Asset deal income | --279.52 | --279.52 | ---- | ---- | ---- | ---- | ---- | -147.70%-8.4K | -147.70%-8.4K | ---2.99K |
| Other revenue | 51.01%47.73M | 12.35%34.95M | -12.08%25.24M | 29.92%41.08M | 245.00%31.61M | 245.18%31.11M | 522.36%28.71M | 341.89%31.62M | 96.31%9.16M | 228.03%9.01M |
| Operating profit | 10.47%-582.9M | 12.33%-378.99M | 13.60%-193.74M | 15.02%-941.3M | 21.46%-651.05M | 15.93%-432.3M | 6.38%-224.23M | -50.54%-1.11B | -62.58%-828.92M | -49.19%-514.2M |
| Add:Non operating Income | ---- | ---- | ---- | --1.65M | --1.4M | ---- | ---- | ---- | ---- | ---- |
| Less:Non operating expense | ---- | ---- | ---- | --3.25K | ---- | ---- | ---- | ---- | ---- | ---- |
| Total profit | 10.27%-582.9M | 12.33%-378.99M | 13.60%-193.74M | 15.16%-939.65M | 21.63%-649.64M | 15.93%-432.3M | 6.38%-224.23M | -50.54%-1.11B | -62.58%-828.92M | -49.19%-514.2M |
| Less:Income tax cost | 1,386.51%52.07K | 3,784.99%52.07K | ---- | -96.20%3.85K | -89.56%3.5K | -97.47%1.34K | ---- | -61.12%101.32K | -85.53%33.57K | -77.13%53.06K |
| Net profit | 10.27%-582.95M | 12.32%-379.04M | 13.60%-193.74M | 15.17%-939.66M | 21.63%-649.65M | 15.94%-432.3M | 6.38%-224.23M | -50.50%-1.11B | -62.51%-828.95M | -49.10%-514.25M |
| Net profit from continuing operation | 10.27%-582.95M | 12.32%-379.04M | 13.60%-193.74M | 15.17%-939.66M | 21.63%-649.65M | 15.94%-432.3M | 6.38%-224.23M | -50.50%-1.11B | -62.51%-828.95M | -49.10%-514.25M |
| Less:Minority Profit | 96.70%-3.01M | 98.08%-1.68M | ---1.23M | ---93.7M | ---91.19M | ---87.55M | ---- | ---- | ---- | ---- |
| Net profit of parent company owners | -3.85%-579.95M | -9.46%-377.36M | 14.15%-192.51M | 23.63%-845.96M | 32.63%-558.46M | 32.96%-344.75M | 6.38%-224.23M | -50.50%-1.11B | -62.51%-828.95M | -49.10%-514.25M |
| Earning per share | ||||||||||
| Basic earning per share | 2.22%-1.32 | -4.82%-0.87 | 14.81%-0.46 | 25.00%-2.04 | 33.50%-1.35 | 34.13%-0.83 | 8.47%-0.54 | -49.45%-2.72 | -61.11%-2.03 | -48.24%-1.26 |
| Diluted earning per share | 2.22%-1.32 | -4.82%-0.87 | 14.81%-0.46 | 25.00%-2.04 | 33.50%-1.35 | 34.13%-0.83 | 8.47%-0.54 | -49.45%-2.72 | -61.11%-2.03 | -48.24%-1.26 |
| Other composite income | ||||||||||
| Total composite income | 10.27%-582.95M | 12.32%-379.04M | 13.60%-193.74M | 15.17%-939.66M | 21.63%-649.65M | 15.94%-432.3M | 6.38%-224.23M | -50.50%-1.11B | -62.51%-828.95M | -49.10%-514.25M |
| Total composite income of parent company owners | -3.85%-579.95M | -9.46%-377.36M | 14.15%-192.51M | 23.63%-845.96M | 32.63%-558.46M | 32.96%-344.75M | 6.38%-224.23M | -50.50%-1.11B | -62.51%-828.95M | -49.10%-514.25M |
| Total composite income of minority owners | 96.70%-3.01M | 98.08%-1.68M | ---1.23M | ---93.7M | ---91.19M | ---87.55M | ---- | ---- | ---- | ---- |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | -- | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
HK Tech and Internet Stocks HK Tech and Internet Stocks
Stocks of companies primarily involved in technology and internet sectors in the HK stock market. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.
View More
Nancy Pelosi Portfolio Nancy Pelosi Portfolio
Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns. Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns.
Hot Topics Hot Topics
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"